Beigel et al.1616 Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813-1826. https://doi.org/10.1056/NEJMoa2007764 https://doi.org/10.1056/NEJMoa2007764...
|
RCT |
Adults hospitalized with COVID-19 with pulmonary impairment Different severity levels of COVID-19 |
(N = 541) Remdesivir: 200 mg i.v. on day 1, followed by 100 mg on days 2-10 or until discharge or death |
(N = 521) Placebo |
Mortality in 15 and 29 days Mechanical ventilation or ECMO Time to recovery (discharge or hospitalization for infection control) Clinical improvement (recovery scale) Severe adverse events |
29 days |
Spinner et al.1919 Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(11):1048-1057. https://doi.org/10.1001/jama.2020.16349 https://doi.org/10.1001/jama.2020.16349...
|
RCT |
Patients hospitalized with SARS due to COVID-19 (pulmonary abnormalities and SpO2 < 94% on room air = moderate to severe disease) |
(N = 197) Remdesivir: 200 mg on day 1, followed by 100 mg on days 2-10 (N = 199) Remdesivir: 200 mg on day 1, followed by 100 mg on days 2-5 |
(N = 200) Standard of care corticosteroid, hydroxychloroquine, azithromycin, lopinavir-ritonavir |
Mortality Mechanical ventilation or ECMO Recovery rate (recovery scale) Clinical improvement (recovery scale) Severe adverse events |
28 days |
Wang et al.2020 Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [published correction appears in Lancet. 2020 May 30;395(10238):1694]. Lancet. 2020;395(10236):1569-1578. https://doi.org/10.1016/S0140-6736(20)31022-9 https://doi.org/10.1016/S0140-6736(20)31...
|
RCT |
Adult patients hospitalized with COVID-19 and onset of symptoms by 12 days SpO2 < 94% on room air, PaO2/FIO2 ratio < 300, or radiological viral pneumonia Severe COVID-19 |
(N = 158) Remdesivir: 200 mg i.v. on ICU day 1, followed by 100 mg i.v. on days 2-10 Concomitant use of lopinavir-ritonavir, interferon, and corticosteroids |
(N = 79) Placebo |
Mortality Clinical improvement (recovery scale or discharge) Severe adverse events |
28 days |
WHO Solidarity Trial Consortium et al.1818 WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511. https://doi.org/10.1056/NEJMoa2023184 https://doi.org/10.1056/NEJMoa2023184...
|
RCT |
Adult (≥ 18 years) patients hospitalized with COVID-19 Different severity levels of COVID-19 |
(N = 2,750) Remdesivir: 200 mg on day 0, followed by 100 mg on days 1-9 |
(N = 4,088) Standard of care, corticosteroids, convalescent plasma, anti-IL-6 drug |
Mortality Mechanical ventilation or ECMO |
28 days |
Mahajan et al.1717 Mahajan L, Singh AP, Gifty. Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study. Indian J Anaesth. 2021;65(Suppl 1):S41-S46. https://doi.org/10.4103/ija.IJA_149_21 https://doi.org/10.4103/ija.IJA_149_21...
|
RCT |
Adult (18-60 years) patients hospitalized with moderate to severe COVID-19 within the last 4 days with viral pneumonia, RR > 24 breaths/min, and SpO2 < 94%, not on mechanical ventilation or presenting with multiple organ failure |
(N = 34) Remdesivir: 200 mg i.v. on day 1, followed by 100 mg on days 2-5 Concomitant use of heparin and corticosteroids |
(N = 36) Standard of care, corticosteroids, heparin |
Mortality Mechanical ventilation Recovery rate (recovery scale) Adverse events |
24 days |
Ader et al.2121 Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial [published online ahead of print, 2021 Sep 14]. Lancet Infect Dis. 2021;S1473-3099(21)00485-0. |
RCT |
Adult (≥ 18 years) patients hospitalized with moderate to severe COVID-19, based on clinical assessment and SpO2 < 94% or requiring supplemental oxygen, noninvasive ventilation, or mechanical ventilation |
(N = 414) Remdesivir: 200 mg i.v. on day 1, followed by 100 mg i.v. on days 2-10 |
(N = 418) Standard of care, corticosteroids, heparin |
Clinical status at days 15 and 29 Time to improvement Time to hospital discharge Mortality |
29 days |
Kalligeros et al.2222 Kalligeros M, Tashima KT, Mylona EK, Rybak N, Flanigan TP, Farmakiotis D, et al. Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience. Open Forum Infect Dis. 2020;7(10):ofaa319. https://doi.org/10.1093/ofid/ofaa319 https://doi.org/10.1093/ofid/ofaa319...
|
OCS |
Adult patients hospitalized with COVID-19 and SpO2 < 94% or requiring supplemental oxygen Pulmonary abnormalities, creatinine clearance > 50 mL/min, AST and ALT < 5 upper limit unit of normal |
(N = 99) Remdesivir: 200 mg on day 1, followed by 100 mg on days 2-10 |
(N = 125) Standard of care, corticosteroids, convalescent plasma, hydroxychloroquine |
Mortality Clinical improvement Length of hospital stay |
28 days |
Ohl et al.2323 Ohl ME, Miller DR, Lund BC, Kobayashi T, Richardson Miell K, Beck BF, et al. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19. JAMA Netw Open. 2021;4(7):e2114741. https://doi.org/10.1001/jamanetworkopen.2021.14741 https://doi.org/10.1001/jamanetworkopen....
|
OCS |
Positive test for SARS-CoV-2 within 14 days prior to or during hospitalization Creatinine clearance > 50 mL/min, AST e ALT < 5 upper limit unit of normal |
(N = 1,172) Remdesivir |
(N = 1,172) Standard of care, corticosteroid, hydroxychloroquine, azithromycin, heparin |
Mortality Length of hospital stay |
30 days |
Olender et al.2424 Olender SA, Walunas TL, Martinez E, Perez KK, Castagna A, Wang S, et al. Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. Open Forum Infect Dis. 2021;8(7):ofab278. https://doi.org/10.1093/ofid/ofab278 https://doi.org/10.1093/ofid/ofab278...
|
OCS |
Adult (≥ 18 years) patients hospitalized with COVID-19, SpO2 < 94% or requiring supplemental oxygen Pulmonary abnormalities, creatinine clearance > 50 mL/min, AST e ALT < 5 upper limit unit of normal |
(N = 268) Remdesivir: 200 mg on day 1, followed by 100 mg on days 2-10 |
(N = 1,399) Standard of care, azithromycin, biologic agents, HIV protease inhibitors, hydroxychloroquine, ribavirin |
Mortality |
28 days |